Texas lawmakers showed wisdom. They were cautious about medical marijuana. This caution is now supported by new research. A major review offers critical insights. It highlights limited evidence for many uses. The state recently expanded its medical cannabis program. This expansion added new qualifying conditions. It also increased dispensing licenses. However, science suggests a need for prudence. Health policy must be research-based. It needs constant re-evaluation. New data now provides that basis.
Texas Expands Medical Cannabis Access
Texas significantly expanded its Compassionate Use Program. Governor Greg Abbott signed House Bill 46. This law took effect September 1, 2025. It added new qualifying conditions. These now include chronic pain. Crohn’s disease and IBD are also eligible. Traumatic brain injuries (TBIs) were added. Terminal illnesses and hospice patients can now qualify. The program also expanded product options. Inhalers and vaporizers are now permitted. Smoking cannabis remains prohibited. The state also increased dispensing licenses. It went from three to 15 licenses. Nine were awarded in December 2025. This aims to improve patient access. It especially helps rural Texans.
JAMA Study Reveals Limited Evidence
A comprehensive review was published. It appeared in the Journal of the American Medical Association (JAMA). This study analyzed 124 studies. They were published from 2010 to September 2025. The review focused on cannabis and cannabinoids. Its findings were clear. Evidence is insufficient for most medical uses. Modest benefits were noted only for specific issues. These include chemotherapy-induced nausea. Certain severe seizure disorders also showed modest benefits. These include Dravet and Lennox-Gastaut syndromes. For many other conditions, evidence is lacking. This includes chronic pain and anxiety. These are common reasons people seek cannabis. The review found limited support for these uses.
Risks Outweigh Benefits for Many
The JAMA review also detailed potential risks. High-potency cannabis use is concerning. It is linked to increased psychotic symptoms. Generalized anxiety disorder rates can rise. Cannabis use disorder is another risk. About 29% of users met disorder criteria. Cardiovascular risks are also noted. Daily inhaled cannabis use correlates with heart issues. This includes higher rates of heart attack. Stroke risk also increases. Experts advise caution with these products. The study authors stressed a gap. This gap exists between public perception and science. Many people use cannabis for relief. However, scientific backing is weak for most claims.
Lawmakers’ Prudence is Justified
Texas lawmakers were right to be cautious. Their approach prioritizes evidence. The state resisted broad legalization pushes. It remained wary of unsubstantiated claims. The recent JAMA review supports this stance. It shows why caution is essential. Health policy requires a scientific foundation. The expansion of the Texas program warrants re-evaluation. This is especially true for newly added conditions. The discourse around cannabis is trending. Many popular news outlets cover it. However, policy should not chase trends. It must follow robust scientific findings. This approach protects patients. It ensures safe and effective treatments.
Balancing Access and Evidence
Moving forward, Texas must balance access. Patients with specific, evidence-backed needs should receive care. However, expansion must be guided by research. The state can foster more research. This will build a stronger evidence base. Future policy decisions can then be more informed. The ongoing news cycle often focuses on quick wins. Yet, the true benefit lies in careful, data-driven progress. This careful approach is vital for public health. It ensures medical cannabis is used wisely. The trending narrative about cannabis needs scientific grounding. This ensures patient safety. It also promotes effective medical practice.
